Abbott Laboratories Remains Structurally Undervalued

Impact · against what's priced in

Abbott Laboratories is a strong buy driven by upward FY26 guidance revisions and a significant valuation gap relative to peers. The acquisition of Exact Sciences and CGM expansion provide concrete growth catalysts that support a structural rerating.

ABT+0.70

No priced-in read yet

In context

The raise in FY26 sales and EPS guidance, combined with a 17.1% P/E discount to peers, suggests immediate upside potential.

Read from the article alone

• ABT▲700%
• guidance
• valuation
• healthcare
• earnings
• EXAS
• acquisition
• diagnostics

Top 1 mover · tap to explore